Histological clearance of isSCC lesions as determined by central pathology review upon completion of treatment.

Complete histological clearance of tumor cells.

To measure the rate of recurrence in patients who have undergone keloidectomy surgery alone versus those who have undergone surgery plus administration of STP705 evaluated at three months, six months, and 12 months post-surgical excision.

To measure the safety, tolerability, and efficacy for treatment of Skin Hypertrophic Scars caused as a result of abnormal healing following surgical procedures.

To determine the number of patients with histological clearance (HC) of facial isSCC lesions at the end of treatment with STP705.

To determine the maximum tolerated dose and to establish the recommended dose for future Phase Ⅱ clinical trials.

To assess injection comfort, characterize local and systemic safety, and evaluate histological changes of subcutaneous doses of STP705, and to compare the safety and tolerability of three different concentrations of STP705 to select dosages for future studies.

To determine maximum tolerated dose and establish dosage recommendations for future Phase II studies.

The safety, tolerability and pharmacokinetics of STP707.